P/E Ratio (TTM)
-50.22
Ascendis Pharma A/S currently has a P/E ratio of -50.22. The P/E ratio is a primary valuation multiple used to determine if a stock is overvalued or undervalued relative to its earnings.
Quarterly P/E
| Quarter | P/E Ratio |
|---|---|
| 2013-03-31 | 71.61 |
| 2013-06-30 | 70.16 |
| 2013-09-30 | 52.50 |
| 2013-12-31 | 16.40 |
| 2014-03-31 | -73.51 |
| 2014-06-30 | -17.18 |
| 2014-09-30 | -31.87 |
| 2014-12-31 | -16.51 |
| 2015-03-31 | 60.71 |
| 2015-06-30 | -6.29 |
| 2015-09-30 | -13.20 |
| 2015-12-31 | -8.79 |
| 2016-03-31 | -4.97 |
| 2016-06-30 | -5.64 |
| 2016-09-30 | -6.17 |
| 2016-12-31 | -9.47 |
| 2017-03-31 | -8.46 |
| 2017-06-30 | -6.42 |
| 2017-09-30 | -7.38 |
| 2017-12-31 | -8.96 |
| 2018-03-31 | -11.39 |
| 2018-06-30 | -26.01 |
| 2018-09-30 | -18.55 |
| 2018-12-31 | -17.97 |
| 2019-03-31 | -20.44 |
| 2019-06-30 | -21.09 |
| 2019-09-30 | -41.86 |
| 2019-12-31 | -18.46 |
| 2020-03-31 | -19.35 |
| 2020-06-30 | -16.71 |
| 2020-09-30 | -14.24 |
| 2020-12-31 | -13.14 |
| 2021-03-31 | -23.51 |
| 2021-06-30 | -11.11 |
| 2021-09-30 | -23.40 |
| 2021-12-31 | -15.02 |
| 2022-03-31 | -11.98 |
| 2022-06-30 | -15.22 |
| 2022-09-30 | -8.71 |
| 2022-12-31 | -7.70 |
| 2023-03-31 | -12.50 |
| 2023-06-30 | -9.47 |
| 2023-09-30 | -7.68 |
| 2023-12-31 | -18.56 |
| 2024-03-31 | -15.35 |
| 2024-06-30 | -16.36 |
| 2024-09-30 | -19.79 |
| 2024-12-31 | -51.65 |
| 2025-03-31 | -22.84 |
| 2025-06-30 | -56.97 |
| 2025-09-30 | -42.35 |
| 2025-12-31 | -83.76 |
Annual P/E
| Year | P/E Ratio |
|---|
* P/E ratios are calculated using trailing twelve-month (TTM) earnings. Extreme values may indicate earnings anomalies or cyclical volatility.